Gilead Sciences (GILD) Total Non-Current Liabilities (2009 - 2026)
Gilead Sciences posted quarterly Total Non-Current Liabilities of $31.6 billion for Q1 2026, down 12.37% year-on-year from $36.0 billion in Q1 2025, and down 10.9% on a QoQ basis from $35.4 billion in Q4 2025.
Gilead Sciences (GILD) has 18 years of Total Non-Current Liabilities data on file, last reported at $31.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 12.37% year-over-year to $31.6 billion; the trailing twelve-month figure through Mar 2026 stood at $31.6 billion (down 12.37% YoY), and the FY2025 full-year result was $35.4 billion, down 8.98% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $31.6 billion, down from $35.4 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $42.2 billion in Q1 2022 and bottomed at $31.6 billion in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $37.4 billion (2024), against an average of $37.5 billion.
- The widest annual swing landed in 2024, when Total Non-Current Liabilities decreased 14.85%; it then gained 3.85% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $40.8 billion in 2022, then dropped by 6.59% to $38.1 billion in 2023, then rose by 2.16% to $38.9 billion in 2024, then slipped by 8.98% to $35.4 billion in 2025, then retreated by 10.9% to $31.6 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $31.6 billion (Q1 2026), $35.4 billion (Q4 2025), and $35.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 100.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 31.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.56 Bn |
| Dec 31, 2025 | 35.42 Bn |
| Sep 30, 2025 | 35.81 Bn |
| Jun 30, 2025 | 35.27 Bn |
| Mar 31, 2025 | 36.02 Bn |
| Dec 31, 2024 | 38.92 Bn |
| Sep 30, 2024 | 34.74 Bn |
| Jun 30, 2024 | 33.96 Bn |
| Mar 31, 2024 | 37.44 Bn |
| Dec 31, 2023 | 38.10 Bn |
| Sep 30, 2023 | 38.04 Bn |
| Jun 30, 2023 | 39.89 Bn |
| Mar 31, 2023 | 37.16 Bn |
| Dec 31, 2022 | 40.78 Bn |
| Sep 30, 2022 | 40.39 Bn |
| Jun 30, 2022 | 41.67 Bn |
| Mar 31, 2022 | 42.22 Bn |
| Dec 31, 2021 | 45.91 Bn |
| Sep 30, 2021 | 44.67 Bn |
| Jun 30, 2021 | 47.10 Bn |
| Mar 31, 2021 | 48.19 Bn |
| Dec 31, 2020 | 48.97 Bn |
| Sep 30, 2020 | 42.32 Bn |
| Jun 30, 2020 | 36.77 Bn |
| Mar 31, 2020 | 36.57 Bn |
| Dec 31, 2019 | 37.97 Bn |
| Sep 30, 2019 | 37.51 Bn |
| Jun 30, 2019 | 34.62 Bn |
| Mar 31, 2019 | 34.94 Bn |
| Dec 31, 2018 | 36.22 Bn |
| Sep 30, 2018 | 35.28 Bn |
| Jun 30, 2018 | 42.98 Bn |
| Mar 31, 2018 | 37.90 Bn |
| Dec 31, 2017 | 49.22 Bn |
| Sep 30, 2017 | 37.78 Bn |
| Jun 30, 2017 | 35.23 Bn |
| Mar 31, 2017 | 34.94 Bn |
| Dec 31, 2016 | 35.86 Bn |
| Sep 30, 2016 | 38.12 Bn |
| Jun 30, 2016 | 32.34 Bn |
| Mar 31, 2016 | 32.36 Bn |
| Dec 31, 2015 | 31.36 Bn |
| Sep 30, 2015 | 32.32 Bn |
| Jun 30, 2015 | 21.65 Bn |
| Mar 31, 2015 | 20.43 Bn |
| Dec 31, 2014 | 18.28 Bn |
| Sep 30, 2014 | 14.56 Bn |
| Jun 30, 2014 | 14.44 Bn |
| Mar 31, 2014 | 14.52 Bn |
| Dec 31, 2013 | 10.67 Bn |
| Sep 30, 2013 | 11.01 Bn |
| Jun 30, 2013 | 11.41 Bn |
| Mar 31, 2013 | 11.71 Bn |
| Dec 31, 2012 | 11.58 Bn |
| Sep 30, 2012 | 12.23 Bn |
| Jun 30, 2012 | 12.29 Bn |
| Mar 31, 2012 | 12.48 Bn |
| Dec 31, 2011 | 10.29 Bn |
| Sep 30, 2011 | 6.41 Bn |
| Jun 30, 2011 | 6.37 Bn |
| Mar 31, 2011 | 6.76 Bn |
| Dec 31, 2010 | 5.44 Bn |
| Sep 30, 2010 | 5.53 Bn |
| Mar 31, 2010 | 3.13 Bn |
| Dec 31, 2009 | 3.11 Bn |
| Sep 30, 2009 | 3.22 Bn |
| Jun 30, 2009 | 3.01 Bn |